Weekly funding opportunities

Fri Sep 24 08:06:04 EDT 2021

Pfizer: Global Obesity Aspire Research Grants<https://cdn.pfizer.com/pfizercom/2021-09/2021-2022%20Global%20Obesity%20ASPIRE.pdf?K5KIDbSHZmOf8xK_JkpHapTbEfbFP2DU>
Research in the following areas will be considered:

  *   Pathophysiology and biology of overweight and obesity
  *   Understanding obesity as a disease
  *   Utilizing retrospective databases, generate evidence of optimal management of obesity and co-existing comorbid conditions
Types of research in scope for this RFP are:

  *   Basic science, pre-clinical research, and clinical research that aligns with the in-scope research topics.
  *   Animal experimentation related to human biology.
  *   Physiological, cellular, molecular and translational research
Individual projects requesting up to USD $250,000 will be considered. Research is expected to be completed and submitted for presentation/publication within 3 years of study start. Smaller, high-quality, innovative grant requests with anticipated results within 12-18 months will be enthusiastically considered.
Letter of intent due November 5, 2021. Med-RA deadline to receive draft documents: October 25.

Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-009.html>
The purpose of this funding opportunity announcement (FOA) is to invite pragmatic clinical trial applications to test paradigms designed to address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States when a patient, relative, or care provider indicates concern. Applications must propose pragmatic clinical trials to test paradigms to detect cognitive impairment, including dementia, with adequate power in up to 3 populations including at least two specified populations that experience health disparities. Clinical paradigms proposed for pragmatic clinical trials should have rigorous supporting preliminary data and utilize tools that are simple to use, standardized, integrated into the electronic medical record (EMR) workflow, and ideally take five minutes or less to administer in a primary care clinical setting. Paradigms must provide standardized and implementable turnkey guidance via the EMR to the care provider for follow-up based on results of either “no objective cognitive impairment detected” or “cognitive impairment possible or detected”.
Due November 10, 2021. Med-RA deadline to receive draft documents: October 28.

Human BioMolecular Atlas Program (HuBMAP) Demonstration Project (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-027.html>
The goal of this funding opportunity announcement is to solicit applications that will creatively use datasets and resources from the Human BioMolecular Atlas Program (HuBMAP: https://commonfund.nih.gov/hubmap) to demonstrate their use to address significant biomedical and biological questions. Projects are expected to work closely with the other funded projects as part of the HuBMAP Consortium to provide specific and actionable feedback, validations, tools, software and other resources back to the consortium.
Due November 19, 2021. Med-RA deadline to receive draft documents: November 8.

Robert Wood Johnson Foundation – Evidence for Action: Innovative Research to Advance Racial Equity<https://www.rwjf.org/en/library/funding-opportunities/2021/evidence-for-action--innovative-research-to-advance-racial-equity.html?rid=0034400001rm2ZLAAY&et_cid=2479482>
This funding is focused on studies about upstream causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals’ options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem.
Applications are accepted on a rolling basis. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAS-21-270.html>
This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.
Standard AIDS dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for January 7, 2022 standard AIDS date: December 20 (due to Winter Break).

NSF Integrative Research in Biology (IntBIO)<https://www.nsf.gov/pubs/2021/nsf21622/nsf21622.htm>
This solicitation invites submission of collaborative proposals that tackle bold questions in biology and require an integrated approach to make substantive progress. Integrative biological research spans subdisciplines and incorporates cutting-edge methods, tools, and concepts from each to produce groundbreaking biological discovery. The research should be synergistic and produce novel, holistic understanding of how biological systems function and interact across different scales of organization, e.g., from molecules to cells, tissues to organisms, species to ecosystems and the entire Earth. Such knowledge is critical to inform solutions to societal challenges, including natural resource management, resilience to environmental change, and global food security. Outcomes from integrative research will also inform and guide the development of new technologies that drive the nation’s bioeconomy. Integrative biological research depends on researchers who work in dynamic, diverse, and collaborative interdisciplinary teams. These teams should be fully engaged in the training and education of the next generation of scientists who will be future leaders in integrative research. A vibrant, inclusive, and integrative training environment will therefore produce a new generation of researchers who can navigate across subdisciplines and engage in integrative thinking.
Due January 25, 2022 and fourth Tuesday in January thereafter. Med-RA deadline to receive draft documents: January 11 (due to MLK holiday).

Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 – Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-339.html>
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. To accomplish the stated overarching goal, this FOA will provide support to recipients of Clinical and Translational Science Awards (CTSA) for creative educational activities with a primary focus on research experiences designed to ensure that the participants receive exposure to the scientific and operational principles underlying each step of the translational process so that they can apply these principles to clinical and translational science research areas such as: 1) pre-clinical research, 2) clinical research, 3) clinical implementation, and 4) public health.
Research Experiences:
Research experiences are expected to be relevant to NCATS’ mission of studying translation on a system-wide level, agnostic to a specific disease, to better understand the scientific and operational principles underlying each step of the translational process. The goal is not to focus on specific diseases, but on what is common among them and the translational science process. Examples of research experiences appropriate for career levels include, but are not limited to:

  *   Undergraduates: to provide hands-on exposure to research that reinforces their interest in clinical and translational science and/or prepares them for graduate school matriculation and/or careers in clinical and translational science for graduate and medical, dental, nursing and other health professional students.
  *   Postdoctoral Fellows and Medical Residents: to extend their skills, experiences, and knowledge base in order to engage in clinical and translational science research activities.
  *   Junior Faculty: to enhance their research skills, experiences, and knowledge base relative to clinical and translational science by working with faculty members at a partnering institution.
Proposed research experiences should involve an innovative approach to provide hands-on exposure to clinical and translational science research in a laboratory or a field setting for a full-time (40 hours per week) period of 10 to 15 weeks in order to stimulate the interest and advance the knowledge base of participants to consider further education and training for future careers as clinical and translational science researchers. The proposed programs should provide research experiences that are not available through formal NIH training mechanisms. R25 programs that propose at least 10 weeks, but fewer than 15 weeks, of full-time research experiences are allowed to request continued part-time support for the participants to work on their research projects, up to the equivalent of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Successful participants may be appointed for additional periods of short-term research experiences.
Due January 26, 2022; May 13, 2022; September 16, 2022; January 13, 2023; May 12, 2023; September 15, 2023; January 12, 2024; May 17, 2024; and September 13, 2024. Med-RA deadline to receive draft documents for January 26, 2022 due date: January 12 (due to MLK holiday).

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Standard dates apply. Expires November 6, 2024. Med-RA deadline to receive draft documents for February 5, 2022 due date: January 25.

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-18-913.html>
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Due February 11, 2022; June 10, 2022;October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; and October 11, 2024. Med-RA deadline to receive draft documents for February 11, 2022 due date: January 31.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210924/efa9f300/attachment.html>